Key Highlights
- Shares of Tempus AI surged by 10.67%, reaching $64.63 following Piper Sandler’s upgrade to Overweight with a $76 price projection.
- The positive analyst call was fueled by enthusiasm surrounding the Personalis acquisition and promising clinical trial data.
- The company exceeded Q2 expectations, posting an adjusted loss of $0.04 per share compared to the anticipated $0.14 loss, while revenues grew 21.6% annually to $382.49 million.
- Recent developments include a $9.5 million federal grant for cardiovascular AI research and the launch of a comprehensive whole-genome dataset project.
- Wall Street maintains a Hold consensus with an average target price of $69.33, although multiple analysts have recently increased their projections.
Tempus AI (TEM) shares experienced a significant rally of 10.67% on September 15, with the stock reaching $64.63 during midday sessions, a notable increase from the previous closing price of $62.21. Throughout the trading day, shares peaked at $65.50.
The rally was primarily sparked by a new rating from Piper Sandler, which elevated TEM to Overweight status and established a $76 price objective. The investment firm cited growing confidence in the company’s Personalis acquisition strategy and encouraging clinical trial outcomes as primary factors behind the upgraded rating.
Company founder and CEO Eric Lefkofsky reinforced the optimistic outlook during a recent industry conference, emphasizing potential revenue expansion through enhanced pricing strategies for the firm’s liquid biopsy testing services.
Quarterly Results Exceed Wall Street Forecasts
Tempus delivered financial results that surpassed analyst projections in its most recent quarter. The healthcare technology firm recorded an adjusted loss of $0.04 per share, significantly outperforming the consensus forecast of a $0.14 loss.
Quarterly revenue totaled $382.49 million, slightly exceeding Wall Street’s expectation of $379.69 million. This figure reflected a year-over-year revenue increase of 21.6%.
While the revenue performance impressed investors, the company continues to operate at a loss. Tempus reported a net margin of negative 17.77% and return on equity of negative 50.28%.
New Growth Drivers Emerge
In addition to the analyst upgrade, market participants are monitoring two significant recent announcements. The company secured a $9.5 million federal grant to advance its artificial intelligence capabilities in cardiovascular medicine.
Tempus also unveiled a major whole-genome sequencing dataset project designed to enhance its AI-powered diagnostic tools and strengthen its data infrastructure. These strategic initiatives underscore the company’s commitment to expanding its presence among healthcare providers and pharmaceutical industry partners.
Guggenheim increased its price objective from $60 to $65 while maintaining a Buy recommendation. Needham kept its Buy stance with a $75 target. HC Wainwright elevated its projection from $56 to $66.
Wall Street’s consensus rating currently stands at Hold, with an average price target of $69.33 based on coverage from 21 analysts. The breakdown includes 11 Buy ratings, eight Hold recommendations, and two Sell ratings.
Institutional ownership has been expanding steadily. Sumitomo Mitsui Trust Group increased its holdings by 23.4% during the first quarter, while Franklin Resources boosted its position by 27.9% in the fourth quarter. Institutional shareholders collectively control 24.22% of outstanding shares.
Regarding insider transactions, EVP Andrew Polovin divested 7,927 shares at $56.00 per share on August 19, and CEO Ryan Fukushima sold 14,286 shares at $70.00 each on August 21. Over the past three months, company insiders have sold approximately $56.96 million worth of stock.
The stock’s 50-day moving average is positioned at $55.99, while the 200-day moving average sits at $52.33. The company maintains a debt-to-equity ratio of 3.06 and displays a beta coefficient of 3.72, indicating substantial price volatility.
As of September 15, Tempus AI’s market capitalization stands at approximately $10.65 billion.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
